Mizuho reiterates BridgeBio stock rating ahead of Pfizer trial

Mizuho reiterated an Outperform rating and $106 price target on BridgeBio Pharma ahead of the April 27-May 1 bench trial over Pfizer’s tafamidis 2035 patent. The firm said an outright win could lift BBIO into the $100-$110 range or higher, while investors currently model IP protection closer to year-end 2028. Multiple other analysts remain positive, with targets ranging from $100 to $157, and recent NDA progress for BBP-418 adds to the bullish backdrop.

Analysis

BBIO is trading like a legal binary with a strong embedded optimism premium, but the market is still not fully pricing the path-dependent nature of the event. The key nuance is that this is less about whether Attruby keeps growing and more about how much duration investors are willing to assign to that growth curve; a favorable Pfizer outcome can paradoxically be a near-term positive for BBIO if it removes a stale overhang and forces the street to re-rate the company on execution rather than litigation fear.

The second-order dynamic is positioning. When a stock has already rerated on product momentum, the last leg often comes from a catalyst that clears the “unknown unknown” and unlocks multiple expansion from fund managers who could not own it into a patent event. That makes the next several trading sessions more important than the trial date itself: implied volatility should stay bid, and any leak of legal sentiment could move the stock faster than the eventual ruling.

The consensus likely underestimates how asymmetric the downside is relative to the upside if the legal overhang is removed. A clean or settlement-aligned outcome would not only support Attruby but also improve the financing and valuation optics for the pipeline, since investors can capitalise longer-dated assets with less haircut. The contrarian risk is the opposite: if the court signals that patent protection is weaker than assumed, the move may gap lower quickly because the stock has already become a crowded quality-growth vehicle rather than a cheap litigation lottery ticket.

Key Decisions for Investors

• Own BBIO into the trial window via a defined-risk call spread instead of outright stock; use 1-3 month maturities to capture the catalyst while limiting downside if the legal read turns adverse.
• If already long BBIO, trim 20-30% ahead of the hearing and re-add only on post-trial confirmation; the setup is better for event-driven exposure than for an undisciplined hold.
• Pair trade: long BBIO / short a basket of higher-duration biotech names with weaker near-term catalysts to isolate litigation de-risking versus broader biotech multiple compression.
• For traders willing to lean into volatility, buy BBIO straddles only if the next 1-2 sessions see an implied-volatility reset lower; otherwise the premium is likely too rich given event risk decay.